The aim of the study is to identify and characterize lesions in the abdominopelvic region detected by 18fluorine- fluorodeoxyglucose (FDG) positron Emission Tomography combined Computed Tomography (PET/CT) scan, including determining their malignant or benign nature, and to determine the extent of disease to facilitate proper management
Inclusion criteria: All of the patients were suspected of having malignancy (new, recurrent or metastatic) based on pathology or conventional radiological studies and were referred to nuclear medicine unit for 18F-FDG-PET-CT scan
patients underwent recent abdominal or pelvic surgery.
patients with blood glucose level ˃200 mg/dL
Pregnancy
patients were suspected of having malignancy (new, recurrent or metastatic) based on pathology or conventional radiological studies and were referred to nuclear medicine unit for 18F-FDG-PET-CT scan
Other
Cross-sectional
PET/CT
Devicepositron emission tomography/computed tomography
Evaluate the performance of 18F FDG PET/CT
identify and characterize abdominopelvic lesions, initial staging, follow up of treatment and detection of recurrence in the abdominopelvic region, including determining their malignant or benign nature, and to determine the extent of disease, Assess the spread of disease to lymph nodes, distant metastases, or other areas, to facilitate proper management.
Evaluate the diagnostic power of alternative technologies
Evaluate the diagnostic power of alternative technologies like dual time point images, bladder evacuation and forced diuresis in characterizing abdominopelvic lesions.
Click on the lead sponsor to view all of their trials.
This trial is not recruiting at the moment. You can still explore other options:
